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Background: Patients with chronic HCV infection have increased liver iron. Recently identified protein hepcidin
synthesized in the liver, is thought to be a key regulator for iron homeostasis and is induced by infection and
inflammation. Lower erythropoietin and iron supplementation requirements were previously reported in HD
patients with HCV infection. We investigated the association of prohepcidin with inflammation and iron parameters
in HD patients with and without chronic HCV infection.
Methods: Sixty patients (27 male, 33 female, mean age 50 ±15 years) on chronic HD were included. Parameters
related to iron metabolism (ferritin, serum iron and total iron binding capacity (TIBC)), inflammation (hs-CRP, TNF-α
and IL-6) and prohepcidin levels were measured. The response to treatment (erythropoiesis-stimulating agent (ESA)
resistance index) was assessed from the ratio of the weekly erythropoietin (rhuEPO) dose to hemoglobin (Hb) per
unit weight.
Results: Serum prohepcidin levels of HCV positive patients (135 ± 25 ng/mL) were significantly lower than HCV
negative patients [148 ± 18 ng/mL, (p = 0.025)]. Serum IL-6 levels of HCV positive patients were also significantly
lower than HCV negative patients (p = 0.016). Serum prohepcidin levels were positively correlated with ferritin
(r = 0.405, p = 0.001) and IL-6 (r = 0.271, p = 0.050) levels in HD patients. In the HCV positive group, serum
prohepcidin levels significantly correlated with ferritin levels (r = 0.514 p = 0.004). In the HCV negative group, serum
prohepcidin levels significantly correlated with serum IL-6 levels (r = 0.418, p = 0.027). In multiple regression analysis
performed to predict prohepcidin in HCV positive patients, serum ferritin was found to be an independent variable
(r = 0.28, p = 0.008).
Conclusions: HCV positive HD patients have low levels of serum prohepcidin and IL-6 which might account for
iron accumulation together with lower iron and rhuEPO requirements in these patients.
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Hepatitis C virus (HCV) infection is the most common
cause of chronic liver disease in the world and also com-
mon among chronic hemodialysis (HD) patients [1]. The
prevalence of HCV infection in chronic HD patients has
been estimated to be between 5 and 40% [2,3]. Patients
with chronic HCV infection often have increased liver
iron, however, little is known about the mechanism of* Correspondence: alayildiz@yahoo.com; alaattiny@hotmail.com
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reproduction in any medium, provided the oriron accumulation in the liver [4]. Recently identified
protein hepcidin, a 25-amino acid peptide hormone ex-
clusively synthesized in the liver, is thought to be a key
regulator for iron homeostasis and is induced by infec-
tion and inflammation [5-7]. In HD patients, compared
to healthy controls, higher levels of prohepcidin and
hepcidin associated with chronic inflammation were
reported [7,8]. High levels of hepcidin in these patients
were found to be related to an increased inflammation
and resistance to recombinant human erythropoietin
(rhuEPO) therapy [7,8]. Serum levels of prohepcidin, the
precursor molecule of hepcidin, were found lower inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of this molecule were found negatively associated with
total iron stores in non-uremic patients with chronic
HCV infection [9-11]. However, changes in hepcidin regu-
lation have not been examined previously in HD patients
with chronic HCV. We previously reported that lower
erythropoietin and iron supplementation requirements in
HD patients with HCV infection [12]. Impaired hepcidin
regulation may play a role in alterations of iron metabol-
ism in HD patients with HCV infection. In order to ad-
dress this question, we investigated the association of
prohepcidin with inflammation and iron parameters in
HD patients with and without chronic HCV infection.
Methods
Patients
In our clinic, among 165 HD patients, 30 HD patients
with chronic hepatitis C were selected according to in-
clusion criteria. After selection of the HCV positive pa-
tient group, the controls for each case were chosen from
HCV negative patients, who were matched for age, sex
and time under HD, in the same center. Sixty patients
(27 male, 33 female, mean age 50 ± 15 years) on chronic
HD for a mean time of 80 ± 51 months were included in
the study. Of all study patients 30 had chronic HCV in-
fection and the remaining 30 had negative anti-HCV
test. A review of medical records including information
on age, sex, baseline weight, time on HD treatment, the
etiology of end stage renal disease (ESRD), serologic test
results for viral hepatitis, cardiovascular disease risk
factors, cardiac, thyroid and liver functions were
undertaken. Twenty healthy subjects, aged between 27
and 57 years, were included as a control population. In
HD study group, patients were receiving thrice weekly
dialysis for a 4 hour period with a standard bicarbonate-
containing dialysate bath, using biocompatible HD mem-
brane (Polysulphone, FX-80 series, Fresenius, Germany).
Blood flow rates ranged from 250 to 300 mL/min, while
dialysate flow rate was kept constant at 500 mL/min. All
HD patients were maintained at their target dry body
weight and received an adequate dose of dialysis (double
pool Kt/V≥1.4). In the HCV positive group, none of the
patients had clinical (ascites, edema, jaundice, collateral
circulation and splenomegaly) and radiological findings of
hepatic cirrhosis. Patients in the HCV positive group were
not receiving anti-viral therapy during the course of the
study. The following patients were excluded from the
study; (1) patients positive for hepatitis B virus surface
antigen (HBsAg) (2) patients with previously diagnosed
nonrenal cause of anemia other than iron deficiency (3)
patients with an evidence of active or occult bleeding (4)
patients who received blood transfusion within the past
4 months (5) patients with a history of malignancy, end-
stage liver disease, or chronic hypoxia (6) patients with ahistory of recent hospitalization or infection requiring
antibiotics within the past 4 weeks. Iron status was defined
and iron requirement was supplied according to K/DOQI
guidelines [13].
Our examinations of the patients conformed to good
medical and laboratory practices and the recommenda-
tions of the Declaration of Helsinki on Biomedical
Research involving Human Subjects. This study was
approved by Ethical Committee of Istanbul School of
Medicine. This study is registered to ClinicalTrials.gov,
number NCT01272479.
Laboratory data
Fasting serum samples were obtained in the early morning
for biochemical studies. All biochemical blood samples
were collected before the mid-week HD session in study
group. Most laboratory values including complete blood
cell counts and serum levels of urea nitrogen (BUN),cre-
atinine, electrolytes, calcium, phosphorus, total protein,
albumin, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), total cholesterol, high-density
lipoprotein (HDL)-cholesterol, low-density lipoprotein
(LDL)-cholesterol, very low-density lipoprotein (VLDL)-
cholesterol, triglycerides, ferritin, iron and total iron
binding capacity (TIBC), were measured by standard
enzymatic procedures. Transferrin saturation (TSAT) was
calculated as serum iron/total iron binding capacity. The
response to treatment (erythropoiesis-stimulating agent
(ESA) resistance index) was assessed from the ratio of the
weekly erythropoietin (rhuEPO) dose to hemoglobin (Hb)
per unit weight, yielding a continuous variable (weekly
dose of rHuEPO/Hb/kg). High sensitive CRP (hs-CRP)
(nephelometric method, Dade Behring, Germany, Cata-
logue No:0QIY), IL-6 (Human IL-6 ELISA BMS213/2CE
Bender MedSystems GmbH, Vienna, Austria) and tumour
necrosis factor alpha (TNF-α) (human TNF-immunoassay
kit, BioSource International, Inc., Camarillo, California,
USA) levels were also measured as markers of inflamma-
tion. Kt/V was used to estimate dialysis dose. The serum
level of prohepcidin (Hepcidin Prohormone ELISA kit,
DRG Instruments GmbH, Marburg, Germany) was deter-
mined by using a validated enzyme-linked immunosorb-
ent assay (ELISA) kit. All blood samples were collected
pre-dialysis with the exception of the post-dialysis serum
urea nitrogen to calculate urea kinetics. The HCV
antibody status was examined using the third generation
of HCV enzyme immunoassay (EIA version 2.0; Abbott
Laboratories, Abbott Park, IL).
Total iron received for each patient was defined as
total iron treatment dose administered over the 12-
months time period before the collection of serum sam-
ples for laboratory tests. The mean rhuEPO per week
and the total rhuEPO dose during 12-month were also
calculated.
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The statistical analysis was carried out by Statistical Package
for Social Sciences for Windows ver. 15.0 (SPSS Inc.,
Chicago, IL, USA). Data are expressed as mean±SD, with
significance level p< 0.05. For dichotomous variables the
frequency of positive occurrences were given along with
their corresponding percentages. Median values and per-
centile 25 and percentile 75 were used to present the results
of variables with a non-normal distribution. Parametric and
nonparametric tests were used according to the distribution
pattern of the data of each variable. Statistical comparisons
of individual groups were based on Student’s t test for
continuous variables and on Fisher’s exact test for discrete
variables. All statistical tests performed were two sided and
the level of significance was 0.05. In correlation analysis
between numerical parameters for non-normal distributed
variables, Pearson’s correlation test was used with
transformed data. Multiple linear regression model was
used to identify the independent determinants of outcome
variable after adjustment for potential confounding factors







Gender (M/F) 13/7 27/33
Age (range), years 38 ± 8 (27–57) 50 ± 15 (18–82)
BMI (kg/m2) 24.4 ± 2.7 24.1 ± 4.3
Systolic BP (mm Hg) 113 ± 10 119 ± 17
Diastolic BP (mm Hg) 71 ± 8 74± 16
Time on HD (months) - 80 ± 51
Diabetes, n (%) - 2 (3.3%)
Laboratory data
WBC count, 109 cells/L 6.8 ± 1.4 6.6 ± 2.1
Haemoglobin (g/dL) 14.0 ± 1.4 11.7 ± 1.4
Haematocrit (%) 40.9 ± 3.9 34.6 ± 4.5
Fasting glucose (mg/dL) 80.7 ± 6.7 88.6 ± 16.0
Serum creatinine (mg/dL) 0.87 ± 0.19 8.81 ± 2.08
Total cholesterol (mg/dL) 179 ± 44 165 ± 41
HDL-cholesterol (mg/dL) 36 ± 12 36 ± 12
LDL-cholesterol (mg/dL) 110 ± 33 91 ± 33
Triglycerides (mg/dL) 134 ± 61 185 ± 103
Albumin (g/dL) 4.51 ± 0.40 4.00 ± 0.41
ALT (U/L) 28.9 ± 18.5 18.2 ± 14.5
Calcium (mg/dL) 9.2 ± 0.4 8.8 ± 0.8
Phosphorus (mg/dL) 3.3 ± 0.4 5.3 ± 1.3
Abbreviations: HCV: hepatitis C virus, M: male, F: female, BMI: body mass index, BP:
aminotransferase.Results
Patient baseline characteristics
The baseline characteristics of the 60 patients (30
patients in HCV positive group and 30 patients in HCV
negative group) and 20 healthy volunteers were given in
Table 1. The HD patients were older than the healthy
volunteers. There were no differences in gender, body
mass index (BMI), pre-dialysis systolic and diastolic
blood pressure levels between HD patients and healthy
controls. Among laboratory parameters, the serum
concentrations of glucose, creatinine, triglycerides and
phosphorus were significantly higher in the HD group
than the healthy controls. Serum albumin, calcium and
LDL-cholesterol levels were also significantly lower in
the HD group (Table 1).
On comparing HCV positive and negative HD patients,
there were no differences in age, gender, BMI, time on
dialysis, biochemical parameters (serum glucose, creatinine,
total cholesterol, LDL-cholesterol, HDL-cholesterol,
triglycerides, total protein, albumin, calcium and phos-
phorus levels) and complete blood cell counts (leukocytes,pulation including healthy volunteers and maintenance





0.121 14/16 13/17 0.795
<0.001 47 ± 15 (25–82) 52 ± 15 (18–76) 0.226
0.766 23.3 ± 3.3 24.9 ± 5.0 0.145
0.231 118± 18 121 ±20 0.562
0.378 73 ± 19 76 ± 14 0.441
- 92 ± 58 68 ± 42 0.072
- 1 (3.3%) 1 (3.3%) -
0.766 6.27 ± 2.18 6.91 ± 2.09 0.293
<0.001 11.6 ± 1.5 11.7 ± 1.5 0.786
<0.001 34.1 ± 5.1 34.7 ± 4.6 0.855
0.004 89.2 ± 18.3 88.2 ± 14.6 0.830
<0.001 8.50 ± 2.26 9.06 ± 1.87 0.317
0.170 157± 38 170 ± 42 0.235
0.874 38 ± 13 35 ± 11 0.298
0.039 86 ± 28 94 ± 36 0.374
0.040 159± 65 205 ± 122 0.080
<0.001 3.90 ± 0.46 4.10 ± 0.35 0.078
0.021 24.8 ± 17.0 13.5 ± 10.3 0.011
0.027 9.0 ± 0.9 8.7 ± 0.8 0.226
<0.001 5.5 ± 1.4 5.3 ± 1.1 0.577
blood pressure, HD: hemodialysis, WBC: white blood cell, ALT: Alanine
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negative groups (Table 1). The neutrophil/lymphocyte ratio
was similar between HCV positive (2.02±0.64) and negative
(2.79±2.27) groups (p=0.30). As expected, serum concen-
trations of ALT were significantly higher in the HCV
positive patients than HCV negative patients (p=0.011).
Inflammatory and iron parameters
The serum inflammatory and iron parameters of HD
and control groups are shown in Table 2. Serum hs-CRP,
IL-6, TNF-α and ferritin levels were significantly higher
in the HD group than the controls (Table 2). Serum pro-
hepcidin levels were similar between HD and control
groups.
On comparing HCV positive and negative HD
patients, prohepcidin levels of HCV positive patients
(135 ± 25 ng/mL) were significantly lower than HCV
negative patients [148 ± 18 ng/mL, (p = 0.025)], but simi-
lar to healthy controls [137 ± 20 ng/mL (p = 0.780)]
(Table 2). Serum IL-6 levels of HCV positive patients
were also significantly lower than HCV negative patients
(p = 0.016) and higher than healthy controls (p = 0.023).
Serum iron levels and TSAT were significantly higher in
HCV positive patients (p< 0.001 and p< 0.001, respect-
ively). Serum ferritin levels were similar between two
groups. The total iron received over the 12 months
period was significantly lower in the HCV positive
patients [0 mg (0–200)] than the HCV negative patients
[150 mg (0–425)] (p = 0.047). In HCV negative group
the number of patients receiving rhuEPO (n = 17, 57%)
was significantly higher than the HCV positive group
(n = 7, 23%) (p = 0.008). The ESA resistance index values






hs-CRP (mg/L) median (25-75%) 1.83 (0.68-2.79) 8.35 (3.
TNF-alpha (pg/mL) 6.4 ± 4.6 68.0 ±
IL-6 (pg/mL) 3.5 ± 4.2 12.8 ±
Iron parameters
Iron (μg/dL) median (25-75%) 78 (60–118) 71 (57–
TIBC (μg/dL) 289 ± 93 247 ± 5
TSAT (%) 37.2 ± 24.2 35.1 ± 2
Ferritin (ng/mL) 77 ± 76 705± 4
Prohepcidin (ng/mL) 137 ± 20 142± 2
Total iron need (mg/year) median (25-75%)
ESA resistance index
Abbreviations: hs-CRP: high sensitive C-reactive protein, TNF-α: tumour necrosis fac
saturation, ESA: erythropoiesis-stimulating agent.negative patients [0.07 (0.00-6.58) vs 0.03(0.00-6.51)
(p = 0.039)].
Correlations
In the univariate correlation analysis, serum prohepcidin
levels were positively correlated with ferritin (r = 0.405,
p = 0.001) and IL-6 (r = 0.271, p = 0.050) levels in HD
patients. The serum IL-6 levels were also correlated with
ESA resistance index (r = 0.309, p = 0.027). Multiple lin-
ear regression analysis for predicting prohepcidin levels
was performed including serum ferritin and IL-6 levels
in model as possible confounding factors and revealed
that serum ferritin levels were independently associated
with prohepcidin levels (r = 0.45, standardized β=0.380,
p = 0.007) in all HD patients.
In the HCV positive group, serum prohepcidin levels
significantly correlated with time on dialysis (r = 0.428,
p = 0.018) and ferritin levels (r = 0.514 p = 0.004). Serum
levels of prohepcidin were not correlated with age,
serum IL-6, TNF-α, hs-CRP, albumin, hemoglobin levels
and ESA resistance index values. Serum IL-6 levels were
only correlated with serum ferritin levels (r = 0.421,
p = 0.046) and ESA resistance index values in the HCV
positive group (r = 0.461, p = 0.27). Multiple linear
regression analyses for predicting prohepcidin levels was
performed including time on dialysis and serum ferritin
levels in model as possible confounding factors and
revealed that serum ferritin levels were independently
associated with prohepcidin levels (r = 0.612, standar-
dized β=0.628, p = 0.008).
In the HCV negative group, serum prohepcidin levels
significantly correlated with serum IL-6 levels (r = 0.418,
p = 0.027), total iron dose (r = 0.373, p = 0.042) and ESAers and maintenance hemodialysis patients
tients
)





52-16.22) 0.005 12.20 (5.07-21.42) 5.45 (3.25-1.57) 0.181
104.1 0.026 76.1 ± 61.0 61.0 ± 29.6 0.593
10.1 0.021 9.1 ± 7.7 15.8 ± 10.9 0.016
98) 0.395 88 (66–130) 64 (44–75) <0.001
0 0.156 229 ± 54 263 ± 41 0.012
1.4 0.771 46.9 ± 24.1 24.7 ± 11.6 <0.001
20 <0.001 673 ± 503 699± 270 0.579
3 0.417 135 ± 25 148± 18 0.025
0 (0–200) 150 (0–425) 0.047
0.03 (0.00-6.51) 0.07 (0.00-6.58) 0.039
tor alpha, IL-6: Interleukin-6, TIBC: total iron binding capacity, TSAT: Transferrin
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prohepcidin were not correlated with age, serum TNF-α,
hs-CRP, albumin, ferritin and hemoglobin levels in this
group. When multiple regression analysis was performed
including serum IL-6 levels, total iron dose and ESA re-
sistance index in model as possible confounding factors,
serum ferritin levels were found to be independently
associated with prohepcidin levels (r = 0.680, standar-
dized β=0.402, p = 0.032) (Figure 1).
Discussion
In the present study, serum prohepcidin and IL-6 levels
were found to be lower in HD patients with chronic
HCV infection compared to HCV negative HD patients.
To our knowledge, this is the first study to show that
serum prohepcidin levels were significantly lower in HD
patients with chronic HCV and that concentrations of
prohepcidin were associated with serum ferritin levels.
Growing evidence has suggested the potential occur-
rence of dysregulation of the hepcidin system in patients
with chronic viral hepatitis. In a non uremic population,
Nagashima and coworkers [14] have reported that serum
prohepcidin levels were significantly lower in chronic
HCV infection which may be associated with the down-
regulation of hepcidin transcription by HCV induced re-
active oxygen species [10]. There is convincing evidence
that serum hepcidin levels were significantly lower in
patients with hepatitis C [9,15]. However, Lee SH et al.
showed increased serum IL-6 and prohepcidin levels in
patients with hepatitis C [16]. Another study found that
hepatic hepcidin expression levels in chronic liverFigure 1 The correlation analysis between prohepcidin and IL-6 leveldiseases were strongly associated with the serum ferritin
concentration [10]. These findings may explain the
excess iron storage in patients with chronic HCV infec-
tion. However, the data in the literature on relation
among hepcidin prohormone, iron parameters, inflam-
mation and hepatitis C in HD patients are very limited.
The relationships between iron stores and HCV infec-
tion, and low iron requirement in HD patients with
HCV infection are reported previously [12]. In the
present study, HCV positive patients also required lesser
iron treatment and/or rhuEPO. Additionally, serum
levels of iron and TSAT were found significantly higher
in HCV positive HD patients compared to HCV nega-
tive patients. Similarly, lower serum prohepcidin levels
were previously reported in patients with chronic HCV
infection and concentrations of this molecule were nega-
tively associated with total iron stores and contribute to
the low rhuEPO resistance and the need for low doses of
rhuEPO in these patients. [9-11]. Our results suggest
that disordered hepcidin regulation could be another re-
sponsible factor for lower iron and rhuEPO require-
ments in HD patients with chronic hepatitis C.
In recent studies, serum levels of prohepcidin and
hepcidin were found to be significantly higher in HD
patients compared to healthy controls [7,8]. In the
present study, we found no difference in serum prohep-
cidin levels between HD patients and controls. Due to
the case control nature of the present study, half of the
patients were HCV positive who had lower serum
prohepcidin levels than the HCV negative patients. For
that reason, the mean serum prohepcidin levels of thes in HCV negative HD patients (r = 0.418, p = 0.027).
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serum prohepcidin levels of HCV negative HD patients
were significantly higher than the healthy controls,
which is consistent with previous reports [7,8]. There
may be several possible mechanisms of lower prohepci-
din levels in dialysis patients with hepatitis C; 1) the
down-regulation of hepcidin transcription by HCV
induced reactive oxygen species, 2) impaired induction
of hepcidin by IL-6 in the setting of chronic hepatitis C
and 3) the down-regulation of hepcidin expression by
erythropoietin via inhibiting hepcidin transcription in
liver cells [7,8,17].
Inflammation is an important inducer of hepcidin syn-
thesis [18,19]. In HD patients, inflammation is also a
well known feature and actually in our study all the in-
flammation markers including hs-CRP, IL-6 and TNF-α
were found higher compared to healthy controls. The
causes of highly prevalent state of inflammation in HD
patients are multiple, including decreased renal function,
volume overload, comorbidity and intercurrent clinical
events [20]. Additionally, in HD group, serum IL-6 levels
were correlated with prohepcidin levels similar to obser-
vational data derived from the nonuremic population
[18,19]. In the present study, although the correlation
between serum IL-6 and prohepcidin levels were signifi-
cant in HCV negative HD patients, no significant correl-
ation was found between serum IL-6 and prohepcidin
levels in HCV positive HD patients. These findings may
indicate that the hepcidin response to inflammatory
cytokines such as IL-6 may be inappropriate in HCV
positive HD patients which may be one of the mechan-
isms responsible for dysregulation of hepcidin in HD
patients with chronic HCV infection.
Hepatitis C virus infection may result in lower produc-
tion of type 1cytokines including IL-6 [21,22]. The sug-
gested possible mechanism for this finding is the
impairment of monocyte function in patients with
chronic hepatitis C [21]. In the present study, HCV posi-
tive HD patients had also lower serum IL-6 levels as
compared to HCV negative patients. These lower serum
IL-6 levels in HCV positive HD patients may be respon-
sible for the decreased prohepcidin levels in HCV as
compared to HCV negative HD patients.
In the present study, we measured serum prohepcidin
levels, which is one of the limitations. The detection and
quantification of hepcidin in serum have been hampered
by several technical difficulties. However, Costa et al.
reported significant positive correlation between prohepci-
din and hepcidin serum levels [7]. There is also evidence
that prohepcidin levels are reliable indicators of hepcidin
levels and activity [23]. Because of the case control design
of the study, the results can not infer a causal relationship.
This is the second limitation of the study.Conclusions
HCV positive HD patients have low levels of serum pro-
hepcidin and IL-6 which might account for iron accu-
mulation together with lower iron and rhuEPO
requirements in these patients.
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